The Ischemia Reperfusion Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ischemia Reperfusion Injury. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued products.
GlobalData tracks 42 drugs in development for Ischemia Reperfusion Injury by 34 companies/universities/institutes. The top development phase for Ischemia Reperfusion Injury is preclinical with 24 drugs in that stage. The Ischemia Reperfusion Injury pipeline has 39 drugs in development by companies and three by universities/ institutes. Some of the companies in the Ischemia Reperfusion Injury pipeline products market are: Neurolmed, CFM Pharma and Revive Therapeutics.
The key targets in the Ischemia Reperfusion Injury pipeline products market include Mannan Binding Lectin Serine Protease 2, Protein Tyrosine Phosphatase, and Prostacyclin Receptor.
The key mechanisms of action in the Ischemia Reperfusion Injury pipeline product include Mannan Binding Lectin Serine Protease 2 Inhibitor with three drugs in Preclinical. The Ischemia Reperfusion Injury pipeline products include eight routes of administration with the top ROA being Intravenous and 11 key molecule types in the Ischemia Reperfusion Injury pipeline products market including Small Molecule, and Recombinant Peptide.
Ischemia Reperfusion Injury overview
Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.
For a complete picture of Ischemia Reperfusion Injury’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
